NIH – UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement

Liability | Insurance

Annotations

This agreement is between the United States Public Health Service (“PHS” or “Government”) and uniQure B.V., which previously operated as Amsterdam Molecular Therapeutics B.V. (“uniQure” or “Licensee”). The agreement was entered into in November 2011, and amended in May 2013 (“Amendment 1”) and November 2013 (“Amendment 2”). According to an SEC filing by uniQure, the agreement was also amended in 2016, but this amendment does not appear to be publicly available. The amendments were agreed between uniQure and the National Institutes of Health (“NIH”), one of the components of PHS.

Under the agreement, uniQure receives a license to make, use and sell Licensed Products and Licensed Processes using PHS’ AAV5 patents. The license is for: (a) therapeutic products to be delivered to the brain or liver for the treatment of diseases originating in the brain or liver, excluding arthritis (“Exclusive Licensed Field of Use”); (b) treatment of any human disease in any manner (“Non-Exclusive Licensed Field of Use”). The license grants apply worldwide (“Licensed Territory”).

UniQure must make payments to PHS including an initial license issue fee, minimum annual royalties, earned royalties, benchmark royalties and patent prosecution expenses. However, benchmark and earned royalties do not have to be paid in relation to pre-clinical or clinical development collaborations for Ultra-Orphan indications with a non-profit organization or academic institution (“Exempt Collaborator”). Under Amendment 1, uniQure and NIH agreed to a reduction in the payments required for sublicensing in order to expedite the development of therapeutics for rare diseases.

Provision Language

12. NEGATION OF WARRANTIES AND INDEMNIFICATION

[…]

12.6 Licensee agrees to maintain a liability insurance program consistent with sound business practice.

Download Full Agreement

Master Alliance Provisions Guide (MAPGuide)

NIH – UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement

Provision Language

Contact Us

Get In Touch

Browse

Contact Us

Get In Touch

Browse

Sign Up to Our Newsletter

Master Alliance Provisions Guide (MAPGuide)

NIH – UniQure, AAV5 Gene Therapies Exclusive and Non-Exclusive License Agreement

Provision Language

Contact Us

Get In Touch

Browse

Contact Us

Get In Touch

Browse

Title

Sign Up to Our Newsletter

Agreement Type

Select Partner Type

Select Development Stage

Select Technology

Select Issue or Sub-issues